

Primary research

Close relationship of tissue plasminogen activator–plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas

Masami Hoshino*, Yoshikura Haraguchi[†], Hiroyuki Hirasawa[‡], Motohiro Sakai*, Hiroshi Saegusa*, Kazushiro Hayashi*, Naoki Horita* and Hiroyuki Ohsawa*

*Department of Intensive and Critical Care Medicine, Tokyo Police Hospital, Chiyoda-ku, Tokyo, Japan

[†]National Hospital Tokyo Disaster Medical Center, Tachikawa-shi, Tokyo, Japan

[‡]Department of Emergency and Critical Care Medicine, Chiba University School of Medicine, Chuo-ku, Chiba-shi, Chiba, Japan

Correspondence: Masami Hoshino, Department of Intensive and Critical Care Medicine, Tokyo Police Hospital, Fujimi 2-10-41, Chiyoda-ku, Tokyo 102, Japan. Tel: +81 3 3263 1371; fax: +81 3 3239 7856; e-mail: noel2000@aioros.ocn.ne.jp

Received: 1 December 1998

Critical Care 2001, **5**:88–99

Revisions requested: 17 April 2000

Revisions received: 1 June 2000

Accepted: 18 November 2000

© 2001 Hoshino *et al*, licensee BioMed Central Ltd
(Print ISSN 1364-8535; Online ISSN 1466-609X)

Published: 26 February 2001

Abstract

Background: Glucose tolerance (GT) has not been taken into consideration in investigations concerning relationships between coagulopathy and multiple organ dysfunction syndrome (MODS), and endothelial cell activation/endothelial cell injury (ECA/ECl) in septic patients, although coagulopathy is known to be influenced by blood glucose level. We investigated those relationships under strict blood glucose control and evaluation of GT with the glucose clamp method by means of the artificial pancreas in nine septic patients with glucose intolerance. The relationships between GT and blood stress related hormone levels (SRH) were also investigated.

Methods: The amount of metabolized glucose (*M* value), as the parameter of GT, was measured by the euglycemic hyperinsulinemic glucose clamp method, in which the blood glucose level was clamped at 80 mg/dl under a continuous insulin infusion rate of 1.12 mU/kg per min, using the artificial pancreas, STG-22. Multiple organ failure (MOF) score was calculated using the MOF criteria of Japanese Association for Critical Care Medicine. Regarding coagulopathy, the following parameters were used: disseminated intravascular coagulation (DIC) score (calculated from the DIC criteria of the Ministry of Health and Welfare of Japan) and the parameters used for calculating DIC score, protein-C, protein-S, plasminogen, antithrombin III (AT-III), plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator–PAI-1 (tPA-PAI-1) complex. Thrombomodulin (TM) was measured as the indicator of ECl.

Results: There were no significant correlations between *M* value and SRH, parameters indicating coagulopathy and the MOF score. The MOF score and blood TM levels were positively correlated with DIC score, thrombin–AT-III complex and tPA-PAI-1 complex, and negatively correlated with blood platelet count.

Conclusions: GT was not significantly related to SRH, coagulopathy and MODS under strict blood glucose control. Hypercoagulability was closely related to MODS and ECl. Among the parameters indicating coagulopathy, tPA-PAI-1 complex, which is considered to originate from ECA, seemed to be

AP = artificial pancreas; AT-III = antithrombin III; BG = blood glucose level; DIC = disseminated intravascular coagulation; ECA = endothelial cell activation; ECl = endothelial cell injury; GT = glucose tolerance; MODS = multiple organ dysfunction syndrome; mMOF = modified multiple organ failure; NIDDM = noninsulin-dependent diabetes mellitus; PAI-1 = plasminogen activator inhibitor-1; PLT = platelet count; PT = prothrombin time; SRH = stress related hormone; TAT = thrombin–antithrombin III complex; TM = thrombomodulin; tPA = tissue plasminogen activator; T₃ = triiodothyronine; T₄ = thyroxine.

a sensitive parameter of MODS and ECI, and might be a predictive marker of MODS. The treatment for reducing hypercoagulability and ECA/ECI were thought to be justified as one of the therapies for acutely ill septic patients.

Keywords: artificial pancreas, coagulopathy, diabetes mellitus, multiple organ dysfunction syndrome, tissue plasminogen activator-plasminogen activator inhibitor-1 complex

Introduction

Hypercoagulability and decreased fibrinolysis, including increased PAI-1 level, are often found in the clinical field and are considered to be the risk factors of cardiovascular diseases and glucose intolerance, especially in patients with noninsulin-dependent diabetes mellitus (NIDDM) [1–6]. Most of the acutely ill severe patients also have coagulopathy, and they often have glucose intolerance. The relationships between coagulopathy and organ dysfunction/glucose intolerance in the acute ill phase have not, however, been clearly analyzed. Although there are reports investigating the relationship between coagulopathy and organ dysfunction [7–13], and the relationship between coagulopathy and endothelial cell activation/injury [14–17] in septic patients, there is no report investigating the relationship between coagulopathy and GT in septic patients as far as we know. Moreover, parameters related to coagulopathy are known to be influenced directly by the metabolic factors. For example, glucose, insulin, and fat influence the production of PAI-1, which is the important parameter related to coagulopathy [18–23]. In aforementioned reports, however, metabolic factors, especially blood glucose level (BG) that is usually unstable in the septic state, are not taken into consideration.

We have been using the bedside type artificial pancreas (AP) in septic patients with glucose intolerance since 1985 to control BG, to perform effective nutritional support, and to evaluate metabolic disorders including glucose and fat. By strictly stabilizing BG using AP, analyses of the factors including PAI-1 that are influenced by BG are considered to be correctly performed.

The purpose of this study is, first, to analyze the relationships between coagulopathy, including abnormal blood PAI-1-related parameters, and glucose tolerance, MODS, and endothelial cell injury. Second was to investigate which parameters related to coagulopathy were most closely related to glucose tolerance, MODS, and endothelial cell injury, in septic patients with glucose intolerance in whom BG was strictly controlled and the glucose tolerance was evaluated with the glucose clamp method by means of AP. We consider that better understanding of the aforementioned relationships and confirming the useful parameters will be helpful for the early diagnosis of the severity of sepsis and for the treatment of the septic patients.

Materials and methods

The investigated patients were nine septic intensive care unit patients with glucose intolerance in whom BG was strictly controlled by means of AP. We selected the patients with strict blood glucose control by AP in order to exclude the direct influence of BG to the parameters related with coagulopathy, including PAI-1-related parameters, as already mentioned. The patients were all in septic condition, which was defined as the condition with systemic inflammatory response syndrome caused by the infection [24]. To analyze the septic patients with sepsis-induced (or related) glucose intolerance, the diabetes patients and those who had liver or pancreatic diseases as primary diseases were excluded. Six patients had acute respiratory distress syndrome (four caused by panperitonitis, two after intracranial hemorrhage), two had gangrene of a lower extremity, and one had a burn (Table 1). One patient with panperitonitis died.

Regarding administered drugs that might influence glucose tolerance on the day when the GT measurements were performed (total number of measurements, 18 times (days); 2 times (days) for each patient; see later), dopamine was used for 5 patients (6 days out of 10 measured days), prednisolone for 1 patient (2 days out of 2 measured days), and dobutamine for 1 patient (2 days out of 2 measured days). The amount of dopamine used was less than 5 $\mu\text{g}/\text{kg}$ per min (mean, 2.5 ± 1.6 $\mu\text{g}/\text{kg}$ per min [$n = 6$]; all were used for increasing renal blood flow), that of prednisolone was 40 mg/day, and that of dobutamine was 13 and 4 $\mu\text{g}/\text{kg}$ per min.

Analyzed items were as follows. Regarding MODS, the multiple organ failure (MOF) score was calculated using the MOF criteria of the Japanese Association for Critical Care Medicine [25] (Table 2). The maximum of the MOF score is 14. The modified MOF score (mMOF score), in which points of disseminated intravascular coagulation (DIC) (coagulopathy) were excluded, was also calculated when the correlation between coagulopathy and MODS was investigated.

The parameter of glucose metabolism, the *M* value (the amount of metabolized glucose), was measured by the euglycemic hyperinsulinemic glucose clamp method, in which the BG level was clamped (or maintained) at 80 mg/dl under a continuous insulin infusion rate of

Table 1

Primary diseases of the nine septic patients with glucose intolerance

Patient	Age (years)	Sex	Diseases	Prognosis
1	54	F	ARDS (after panperitonitis due to perforation of the ileum)	Alive
2	67	M	ARDS (after panperitonitis due to NOMI)	Alive
3	74	M	ARDS (after panperitonitis due to perforation of the duodenum)	Died
4	49	M	ARDS (after panperitonitis due to necrotic cholecystitis)	Alive
5	47	M	ARDS (after the operation of acute subdural hematoma)	Alive
6	59	M	ARDS (after the operation of subarachnoidal hemorrhage)	Alive
7	66	M	Gangrene of lower extremity	Alive
8	74	M	Gangrene of lower extremity	Alive
9	21	M	Burn	Alive

ARDS, Acute respiratory distress syndrome; F, female; M, male; NOMI, nonocclusive mesenteric ischemia.

Table 2

Multiple organ failure score calculated using the criteria proposed by the Japanese Association for Critical Care Medicine [25]

Impaired organ	Criteria	Points	Impaired organ	Criteria	Points
Kidney	Urine output < 600 ml/day; or 50 mg/dl < BUN; or 3–5 mg/dl creatinine	1	Digestive tract	Hematemesis, melena; or ulcer; or blood transfusion greater than 2 U/day	1
	5 mg/dl < creatinine; or 0 ml/h < CH ₂ O; or 3.0% < FENa	2		bleeding from digestive tract with hypotension, or perforation, necrosis	2
Lung	PaO ₂ < 60 mmHg (room air); or 250 mmHg ≤ PaO ₂ /FiO ₂ < 350 mmHg; or 300–400 mmHg A-aDO ₂ (FiO ₂ = 1.0); or 20–30% Qs/Qt; or with respirator for more than 5 days	1	Brain	10–100 JCS, or 8–12 GCS	1
	PaO ₂ /FiO ₂ < 250 mmHg; or 400 mmHg < A-aDO ₂ (FiO ₂ = 1.0); or 30% < Qs/Qt	2		100 < JCS, or 8 < GCS, or convulsion with unconsciousness, or no auditory brain stem response, or brain death	2
Liver	3.0–5.0 mg/dl bilirubin; or 100 IU/l < s-GPT; or 0.4–0.7 AKBR	1	DIC	20 µg/ml ≤ FDP; or platelet ≤ 80,000/µl; or fibrinogen ≤ 100 mg/dl; or exacerbation of FDP, platelet, fibrinogen within 2 days (more than three times greater than or one-third of normal value), or with heparin (≥50 U/kg per day) or probable DIC	1
	5.0 mg/dl < bilirubin; or AKBR < 0.4	2			
Cardiovascular	10 mmHg < CVP, or major arrhythmia, or Forrester classification: peripheral vascular resistance < 1000 dyne s/cm ⁵ ; or with inotropic agents for more than 2 h	1		Definite DIC	2
	Forrester classification: with shock, or life threatening arrhythmia, or acute myocardial infarction, or cardiac arrest, or major arrhythmia with shock	2			

Judgement of probable disseminated intravascular coagulation (DIC)* and definite DIC* from Criteria of DIC proposed by the Ministry of Health and Welfare of Japan [28]. A-aDO₂, alveolar–arterial oxygen difference; AKBR, arterial ketone body ratio; BUN, blood urea nitrogen; CVP, central venous pressure; FDP, fibrin and fibrinogen degradation products; FENa, fractional excretion of sodium; GCS, Glasgow coma scale; JPS, Japan coma scale.

1.12 mU/kg per min (40 mU/m² per min), using AP. The *M* value is the amount of glucose infusion required to clamp BG, and is the indicator of peripheral glucose tolerance

(normal range, 6–8 mg/kg per min) [26,27]. The daily mean blood glucose level was calculated from the BG measured (sampled) every 1 h.

Table 3**Criteria of disseminated intravascular coagulation (DIC) (The Ministry of Health and Welfare of Japan [28])**

Criteria		Points	
1. Underlined disease	(+)	1	
	(-)	0	
2. Symptom	(1) Bleeding tendency	(+) (-)	1 0
	(2) Symptom caused by organ dysfunction	(+) (-)	1 0
3. Laboratory data	(1) Serum FDP ($\mu\text{g/ml}$)	$40 \leq$ $20 \leq < 40$ $10 \leq < 20$ $10 >$	3 2 1 0
	(2) Platelet ($\times 10^9/\mu\text{l}$)	$50 \geq$ $80 \geq > 50$ $120 \geq > 80$ 120	3 2 1 0
	(3) Plasma fibrinogen (mg/dl)	$100 \geq$ $150 \geq > 100$ $150 <$	2 1 0
	(4) Prothrombin time/control	$1.67 \leq$ $1.25 \leq < 1.67$ $1.25 >$	2 1 0
4. Supplemental data	(1) Detection of soluble fibrin monomer		
	(2) Increase of D-dimer		
	(3) Increase of thrombin-antithrombin complex		
	(4) Increase of plasmin-a ₂ -plasmin inhibitor complex		
	(5) Exacerbation of FDP, platelet, fibrinogen within several days		
	(6) Improvement of data with anticoagulant therapy		
Judgment*			
1. Definite DIC	(1) Patients who do not have leukemia, pernicious anemia, liver cirrhosis, or who are not under cancer chemotherapy	More than 7 or 6 points with more than two of supplemental data	
	(2) Patients who have leukemia, pernicious anemia, or who are under cancer chemotherapy points for bleeding tendency and platelet are not included	More than 4 or 3 points with more than two of supplemental data	
	(3) Patients who have liver cirrhosis	More than 10 or 9 points with more than two of supplemental data	
2. Probable DIC	(1) Patients who do not have leukemia, pernicious anemia, liver cirrhosis, or who are not under cancer chemotherapy	6 points	
	(2) Patients who have leukemia, pernicious anemia, or who are under cancer chemotherapy points for bleeding tendency and platelet are not included	3 points	
	(3) Patients who have liver cirrhosis	9 points	

*Exclusion: this DIC criteria cannot be applied for neonates, pregnant woman, and patients with fulminant hepatitis. FDP, fibrin and fibrinogen degradation products.

The blood concentration of stress hormones (catecholamines [adrenaline, noradrenaline, dopamine], growth hormone, glucagon, cortisol), adrenocorticotrophic hormone, and thyroid-related hormones (thyroid stimulating hormone, triiodothyronine [T_3], free T_3 , thyroxine [T_4], free T_4) were measured because they might influence the GT. Dopamine, dobutamine, and prednisolone were administered when the measurements of the *M* value were performed in some patients as already mentioned.

Regarding coagulopathy, the following parameters were used: DIC score, platelet count (PLT), fibrin and fibrinogen degradation products, fibrinogen, prothrombin time (PT) ratio (PT of the patient divided by control PT), D-dimer, α_2 plasmin

inhibitor-plasmin complex, thrombin-antithrombin III complex (TAT), protein C antigen and activity, protein S antigen and activity, plasminogen, antithrombin III (AT-III), PAI-1 antigen and activity, and tissue plasminogen activator (tPA)-PAI-1 complex. The DIC score was calculated from the DIC criteria of the Ministry of Health and Welfare of Japan [28] (Table 3).

As the indicator of the endothelial cell injury, the blood concentration of thrombomodulin (TM) was measured. Fibrinogen was measured by the thrombin time method, PT by Quick's method, and fibrin and fibrinogen degradation products by the latex agglutination method. TAT, tPA-PAI-1 complex, protein S antigen, protein S activity and TM were measured by enzyme immunoassay, D-dimer and PAI-1

antigen by enzyme-linked immunosorbent assay, and α_2 plasmin inhibitor–plasmin complex and protein C antigen by the Latex photometric immunoassay. AT-III, PAI-1 activity and plasminogen were measured by the synthetic substrate method, and protein C activity by the activated partial thromboplastin time method (SRL Inc Co, Tokyo, Japan).

Data sampling/measurement (blood sampling, MOF/DIC scoring, and glucose clamp method) was performed twice for each patient. The first data sampling/measurement was carried out within 3 days after the admission, and the second data sampling/measurement was performed 1 week after the first data sampling/measurement. Blood sampling was carried out at 08:00 h on the day when the glucose clamp method (the measurement of the *M* value) was performed. We began the glucose clamp method at 09:00 h, when intravenous drip infusion containing glucose for nutritional support was stopped. The daily mean blood glucose level was calculated using the BG during 24 h before the start of the glucose clamp method.

The following points were investigated in turn using the aforementioned data. First, confirmation of the capability of the AP for strict blood glucose control (by calculating the daily mean BG) and for the evaluation of the GT (*M* value). Whether the blood concentration of the stress-related hormones (listed earlier), which are considered to be influenced by sepsis and by the administration of drugs, was related to the GT (*M* value) was also investigated. Third, whether there were any relationships between the glucose tolerance (*M* value) and coagulopathy, MODS (MOF score), and endothelial cell injury (TM) were then investigated. Finally, confirmation of the parameters related to coagulopathy that were most closely correlated with MODS (MOF/mMOF score) and endothelial cell injury (TM).

The AP used was STG-22, manufactured by NIKKISOH Corporation (Tokyo, Japan) (Fig. 1). The AP controls BG by administering insulin or glucose automatically according to the absolute BG and the change of BG, which is measured by continuous blood sampling.

The statistical data are shown as mean \pm standard deviation. Strengths of the relationships between the data are indicated by correlation coefficient *r*, and the correlations between the data are shown by a regression line. The unpaired Student *t* test was used for the comparison of mean values. $P < 0.05$ was considered significant.

Results

Blood glucose control and measurements of the glucose tolerance by means of AP

The mean of the daily mean blood glucose levels and *M* values obtained from the first and second measurements were 183 ± 32 mg/dl ($n = 8$), 4.4 ± 1.4 mg/kg per min

Figure 1



Bedside-type artificial pancreas STG-22.

($n = 7$), and 147 ± 26 mg/dl ($n = 9$), 4.7 ± 1.6 mg/kg per min ($n = 8$), respectively (Table 4). The daily mean blood glucose level could not be calculated in one patient at the first measurement because a blood sampling disorder of AP occurred and a sufficient number of BG data could not be obtained. *M* values could also not be measured in two patients at the first measurement and in one patient at the second measurement because the glucose intolerance was severe and the BG level did not decrease to the clamp level (80 mg/dl).

No significant relationships between the GT and blood stress related hormone levels

There were no significant correlations between the *M* value and blood stress hormone levels (adrenaline, noradrenaline, dopamine, growth hormone, glucagon, cortisol), adrenocorticotrophic hormone, and thyroid-related hormones (thyroid stimulating hormone, T_3 , free T_3 , T_4 , free T_4) (Table 5). We also investigated whether drug (catecholamines [dopamine, dobutamine], glucocorticoids [pre-

Table 4**Blood glucose control and measurements of glucose tolerance by means of artificial pancreas**

	Daily mean blood glucose levels (mg/dl)	Mean <i>M</i> values (mg/kg per min)
First measurement	183 ± 32 (<i>n</i> = 8)	4.4 ± 1.4 (<i>n</i> = 7)
Second measurement	147 ± 26 (<i>n</i> = 9)	4.7 ± 1.6 (<i>n</i> = 8)
Total	164 ± 34 (<i>n</i> = 17)	4.6 ± 1.5 (<i>n</i> = 15)

The first measurement was performed within 3 days after admission, and the second measurement was performed 1 week after the first measurement.

Table 5**No significant correlations between glucose tolerance and blood stress related hormone levels: correlation coefficient (*r*) between the *M* value and hormones**

	Normal range	Mean		<i>r</i>	<i>P</i>	
Adrenaline (ng/ml)	≤0.17	0.11 ± 0.10	(<i>n</i> = 18)	-0.17	< 0.55	(<i>n</i> = 15)
Noradrenaline (ng/ml)	0.15–5.7	0.79 ± 0.74	(<i>n</i> = 18)	0.15	< 0.60	(<i>n</i> = 15)
Dopamine (ng/ml)	≤0.03	19 ± 41	(<i>n</i> = 18)	0.20	< 0.48	(<i>n</i> = 15)
Growth hormone (ng/ml)	0.28–8.70	4.7 ± 5.2	(<i>n</i> = 18)	-0.45	< 0.09	(<i>n</i> = 15)
Glucagon (pg/ml)	23–197	234 ± 156	(<i>n</i> = 18)	0.39	< 0.17	(<i>n</i> = 14)
Cortisol (μg/dl)	5.6–21.3	33 ± 42	(<i>n</i> = 18)	-0.10	< 0.73	(<i>n</i> = 15)
ACTH (pg/ml)	≤60	28 ± 19	(<i>n</i> = 18)	-0.05	< 0.87	(<i>n</i> = 15)
TSH (μU/ml)	0.5–4.8	1.1 ± 1.6	(<i>n</i> = 17)	0.49	< 0.08	(<i>n</i> = 14)
T ₃ (ng/dl)	80–180	82 ± 30	(<i>n</i> = 17)	-0.05	< 0.87	(<i>n</i> = 14)
Free T ₃ (pg/ml)	2.5–4.5	2.2 ± 0.7	(<i>n</i> = 17)	-0.10	< 0.74	(<i>n</i> = 14)
T ₄ (μg/dl)	5.0–13.7	9.4 ± 4.2	(<i>n</i> = 17)	0.09	< 0.76	(<i>n</i> = 14)
Free T ₄ (ng/dl)	0.8–1.9	1.4 ± 0.6	(<i>n</i> = 17)	0.11	< 0.71	(<i>n</i> = 14)

ACTH, Adrenocorticotropic hormone; TSH, thyroid stimulating hormone; T₃, triiodothyronine; T₄ = thyroxine.

donisolone]) administration significantly influenced the glucose tolerance. There was, however, no significant difference between the mean of the *M* values of the patients who were administered those drugs (4.9 ± 1.3 mg/kg per min; *n* = 10) and that of those who were not administered those drugs (4.0 ± 1.7 mg/kg per min; *n* = 5).

No significant correlations between the GT and MODS, coagulopathy

There were no significant correlations between the *M* value and MODS, and parameters related to coagulation and fibrinolysis (Table 6).

Significant correlation between coagulopathy and MODS

The MOF score was strongly correlated with the DIC score (*r* = 0.75, *P* < 0.002), TAT (*r* = 0.72, *P* < 0.002), tPA-PAI-1 complex (*r* = 0.69, *P* < 0.002) and PLT (*r* = -0.68, *P* < .002) among parameters related with coagulation and fibrinolysis (Table 7). Because three of the aforementioned parameters (not the tPA-PAI-1 complex) are used for calculating the MOF score, however, correlations between the

mMOF score, in which the points of coagulopathy of the MOF score are excluded, and parameters related to coagulation and fibrinolysis were also analyzed. The mMOF score was still strongly correlated with TAT (*r* = 0.69, *P* < 0.002), DIC score (*r* = 0.66, *P* < 0.002), PLT (*r* = -0.65, *P* < 0.003) and tPA-PAI-1 complex (*r* = 0.62, *P* < 0.005) (Table 8; Fig. 2).

Significant correlations between endothelial cell injury and MODS, coagulopathy

TM was correlated with MOF score (*r* = 0.92, *P* < 0.002) (Fig. 3), DIC score (*r* = 0.80, *P* < 0.002), tPA-PAI-1 complex (*r* = 0.85, *P* < 0.002), TAT (*r* = 0.85, *P* < 0.002) and PLT (*r* = -0.58, *P* < 0.03) (Table 9; Fig. 4). In one patient, the measurement of TM was performed only once.

Relationships between tPA-PAI-1 complex and other parameters related to coagulation and fibrinolysis

The tPA-PAI-1 complex was positively correlated with DIC score (*r* = 0.74, *P* < 0.002), TAT (*r* = 0.85, *P* < 0.002), and PAI-1 antigen (Table 10).

Table 6

No significant correlations between glucose tolerance and multiple organ dysfunction syndrome, coagulopathy: correlation coefficient (*r*) between the *M* value and the multiple organ failure (MOF) score/parameters related with coagulopathy

	Normal range	Mean		<i>r</i>	<i>P</i>	
MOF score		4.6 ± 1.5	(<i>n</i> = 15)	0.20	< 0.48	(<i>n</i> = 15)
DIC score		4.0 ± 1.8	(<i>n</i> = 18)	0.32	< 0.25	(<i>n</i> = 15)
PLT (/μl)	150,000–280,000	188,000±123,000	(<i>n</i> = 18)	0.39	< 0.15	(<i>n</i> = 15)
FDP (μg/ml)	< 10	14 ± 15	(<i>n</i> = 18)	0.49	< 0.06	(<i>n</i> = 15)
PT ratio	< 1.25	1.3 ± 0.10	(<i>n</i> = 16)	-0.02	< 0.95	(<i>n</i> = 13)
Fibrinogen (mg/dl)	150–350	500 ± 154	(<i>n</i> = 18)	-0.23	< 0.42	(<i>n</i> = 15)
TAT (ng/ml)	≤3.0	13.2 ± 13.0	(<i>n</i> = 18)	0.34	< 0.22	(<i>n</i> = 15)
PIC (μg/ml)	≤0.8	1.2 ± 0.7	(<i>n</i> = 18)	0.27	< 0.34	(<i>n</i> = 15)
D-Dimer (ng/ml)	≤150	750 ± 630	(<i>n</i> = 18)	0.43	< 0.11	(<i>n</i> = 15)
Plasminogen (%)	75–125	80 ± 23	(<i>n</i> = 18)	0.25	< 0.37	(<i>n</i> = 15)
AT-III (%)	70–120	94 ± 28	(<i>n</i> = 13)	0.25	< 0.47	(<i>n</i> = 11)
Protein C activity (%)	55–140	75 ± 43	(<i>n</i> = 18)	0.44	< 0.10	(<i>n</i> = 15)
Protein C antigen (%)	70–150	92 ± 51	(<i>n</i> = 18)	0.47	< 0.08	(<i>n</i> = 15)
Protein S activity (%)	60–150	72 ± 18	(<i>n</i> = 18)	0.42	< 0.12	(<i>n</i> = 15)
Protein S antigen (%)	65–135	83 ± 24	(<i>n</i> = 18)	0.42	< 0.12	(<i>n</i> = 15)
PAI-1 activity (U/ml)	12–15	5.3 ± 3.4	(<i>n</i> = 13)	0.55	< 0.10	(<i>n</i> = 10)
PAI-1 antigen (ng/ml)	≤50	120 ± 86	(<i>n</i> = 18)	0.22	< 0.44	(<i>n</i> = 15)
tPA–PAI-1 complex (ng/ml)	≤11	26 ± 18	(<i>n</i> = 18)	0.27	< 0.34	(<i>n</i> = 15)

AT-III, antithrombin-III; DIC, disseminated intravascular coagulation; FDP, fibrin and fibrinogen degradation products; PAI-1, plasminogen activator inhibitor-1; PIC, α₂ plasmin inhibitor–plasmin complex; PLT, platelet count; PT, prothrombin time; TAT, thrombin–antithrombin complex; tPA, tissue plasminogen activator.

Table 7

Correlation coefficients (*r*) between multiple organ failure score and parameters related to coagulation and fibrinolysis

	<i>r</i>	<i>P</i>	<i>n</i>
DIC score	0.75	< 0.002	18
TAT	0.72	< 0.002	18
tPA–PAI-1 complex	0.69	< 0.002	18
PLT	-0.68	< 0.002	18
Protein S activity	-0.48	< 0.04	18
Plasminogen	-0.43	< 0.08	18
Protein C activity	-0.41	< 0.09	18
D-Dimer	0.38	< 0.12	18
FDP	0.37	< 0.13	18
Protein C antigen	-0.31	< 0.22	18
Protein S antigen	-0.25	< 0.32	18
PAI-1 activity	-0.25	< 0.42	13
PT ratio	-0.23	< 0.40	16
AT-III	0.22	< 0.48	13
PIC	0.2	< 0.43	18
PAI-1 antigen	0.19	< 0.46	18
Fibrinogen	0.000,09	< 1.0	18

AT, Antithrombin; DIC, disseminated intravascular coagulation; FDP, fibrin and fibrinogen degradation products; PAI-1, plasminogen activator inhibitor-1; PIC, α₂ plasmin inhibitor–plasmin complex; PLT, platelet count; PT, prothrombin time; TAT, thrombin–antithrombin complex; tPA, tissue plasminogen activator.


Table 8

Correlation coefficients (*r*) between modified multiple organ failure (mMOF) score* and parameters related to coagulation and fibrinolysis

	<i>r</i>	<i>P</i>	<i>n</i>
DIC score	0.66	< 0.002	18
TAT	0.69	< 0.002	18
PLT	-0.65	< 0.003	18
tPA–PAI-1 complex	0.62	< 0.005	18
Protein S activity	-0.44	< 0.07	18
Protein C activity	-0.43	< 0.08	18
Plasminogen	-0.42	< 0.08	18
Protein C antigen	-0.32	< 0.20	18
D-Dimer	0.3	< 0.23	18
AT-III	0.24	< 0.46	13
Protein S antigen	-0.22	< 0.38	18
PAI-1 activity	-0.21	< 0.50	13
PT ratio	-0.18	< 0.51	16
PAI-1 antigen	0.18	< 0.48	18
PIC	0.16	< 0.54	18
Fibrinogen	0.000,03	< 1.0	18


* mMOF score = MOF score – points of coagulopathy of the MOF score. AT, Antithrombin; DIC, disseminated intravascular coagulation; PAI-1, plasminogen activator inhibitor-1; PIC, α₂ plasmin inhibitor–plasmin complex; PLT, platelet count; PT, prothrombin time; TAT, thrombin–antithrombin complex; tPA, tissue plasminogen activator.

Figure 2



Correlations between mMOF score and parameters related to coagulation and fibrinolysis. The mMOF score (mMOF score = MOF score – the points of coagulopathy of MOF score) was positively correlated with (a) the DIC score, (b) TAT and (d) tPA-PAI-1 complex, and (c) negatively correlated with PLT.

Figure 3



Correlation between TM and MOF score. The MOF score was positively correlated with blood TM level.


Discussion

Acutely ill patients often have coagulopathy and metabolic disorders, including glucose intolerance and abnor-

mal serum fat levels, as well as organ dysfunctions. Those abnormalities seem to be mutually related, but studies concerning relationships among coagulopathy, metabolic disorders, and organ dysfunctions have rarely been reported. One of the reasons for this lack of literature seems to be that metabolic disorders, especially glucose intolerance, are unstable and could not be easily evaluated in acute phase. In this study, we have investigated those relationships under strict blood glucose control and the strict evaluation of the GT with the glucose clamp method by means of AP in septic patients with glucose intolerance.

Although the glucose tolerances of the patients were impaired, blood glucose control by means of AP was good, considering results of the mean of the *M* values and the daily mean BG (Table 4). We could not measure the *M* value three times because the GT was so severe that BG did not decrease to the clamp level (80 mg/dl). This problem was considered to indicate the necessity of the improvement for measuring the *M* value in patients with severe GT (eg increasing the amount of insulin infu-

Figure 4



Correlations between TM and parameters related with coagulation and fibrinolysis. Blood TM levels were positively correlated with (a) the DIC score, (b) tPA-PAI-1 complex and (c) TAT, and (d) negatively correlated with PLT.

sion, stopping intravenous drip infusion earlier than 09:00 h, etc).

There are many factors that influence BG or the GT. Stress hormones and thyroid-related hormones are well known to be included in those factors, and they are also used as the drugs. In the present study in which the AP strictly controlled BG, however, those hormones did not significantly influence the glucose tolerance. This is determined from the results that there were no significant correlations between the *M* value and the blood concentration of these hormones (Table 5), and that there were no significant differences in the *M* values between the patients who were administered these hormones and those who were not. We consider that sepsis induced by some other factors other than these hormones impaired the glucose tolerance.

The relationship between GT including fat metabolism and hypercoagulability, indicated by the increased levels of PAI-1 or tPA-PAI-1 complex, has been well investigated in the patients with NIDDM [5,29,30], with hypertension [31-34], with coronary artery disease [35], and in the normal human subjects or the general population [36,37].

In these studies, PAI-1 or tPA-PAI complex was closely related with, and thought to be caused by, hyperinsulinemia, hyperglycemia, insulin resistance, hypertriglyceridemia, hypercholesterolemia, and increased level of high density lipoprotein cholesterol. *In vitro* studies using endothelial cells, hepatoma cells, or vascular smooth muscle cells showed that PAI-1 was produced by glucose, insulin, free fatty acid, cholesterol, very low density lipoprotein, glucocorticoids, and hyperosmolarity [18-23]. In our study performed under strict blood glucose control by means of AP, however, the glucose intolerance was not a significant factor influencing MODS and coagulopathy, considering from the results that there were no significant correlations between the *M* value and the MOF score, parameters related with coagulation and fibrinolysis (Table 6). In addition, under this strict blood glucose control, BG, blood insulin and fat levels did not significantly influence the coagulopathy, because there were no significant correlations between parameters related with coagulation and fibrinolysis and daily mean BG, blood insulin concentration, and serum fat (triglyceride, total cholesterol, free fatty acid) levels (data not shown). These results are considered to indicate that the

Table 9

Correlation coefficients (*r*) between thrombomodulin (TM) and multiple organ failure (MOF) score, parameters related to coagulation and fibrinolysis*

	<i>r</i>	<i>P</i>	<i>n</i>
MOF score	0.92	< 0.002	17
DIC score	0.80	< 0.002	17
tPA–PAI-1 complex	0.85	< 0.002	17
TAT	0.85	< 0.002	17
PLT	-0.58	< 0.01	17
FDP	0.50	< 0.04	17
D-Dimer	0.48	< 0.05	17
PAI-1 antigen	0.40	< 0.11	17
Protein C activity	-0.38	< 0.13	17
Protein S activity	-0.36	< 0.16	17
PIC	0.33	< 0.20	17
Fibrinogen	-0.31	< 0.23	17
Plasminogen	-0.31	< 0.23	17
Protein C antigen	-0.3	< 0.25	17
AT-III	0.27	< 0.41	12
PT ratio	-0.25	< 0.38	15
Protein S antigen	-0.15	< 0.57	17
PAI-1 activity	-0.04	< 0.90	12

* Mean of TM, 7.3 ± 4.2 FU/ml ($n = 17$); normal range, ≤ 4.5 . AT-III, antithrombin-III; DIC, disseminated intravascular coagulation; FDP, fibrin and fibrinogen degradation products; PAI-1, plasminogen activator inhibitor-1; PIC, α_2 plasmin inhibitor–plasmin complex; PLT, platelet count; PT, prothrombin time; TAT, thrombin–antithrombin complex; tPA, tissue plasminogen activator.

influence of the GT and the factors related with the glucose tolerance (eg BG, blood insulin and fat levels) to coagulopathy could be excluded by the strict blood glucose control using AP.

Relationships between coagulopathy and chronic organ dysfunctions have been well investigated. The hypercoagulable state or decreased fibrinolytic activity in NIDDM patients, shown by increased levels of PAI-1, fibrinogen, factor VII, von Willebrand factor, and tPA, are considered to be risk factors of cardiovascular diseases [1–6,29,38,39]. Increased PAI-1 level is especially thought to be a causative factor of atherosclerosis [5,6,38]. In patients other than those with NIDDM, including those with insulin-dependent diabetes mellitus [40], history of myocardial infarction [41], and hypertension [31–33], hypercoagulable states with increased PAI-1 level are also considered to be one of the risk factors of coronary atherosclerosis or hypertension. Increased PAI-1 level seems to be the cause of, and not only the result of, cardiovascular diseases or atherosclerosis, because it was shown in an animal study that increased expression of PAI-1 in the arterial wall preceded atherosclerosis [6].

Table 10

Correlation coefficients (*r*) between the tissue plasminogen activator–plasminogen activator inhibitor-1 (tPA–PAI-1) complex and other parameters related to coagulation and fibrinolysis

	<i>r</i>	<i>P</i>	<i>n</i>
DIC score	0.74	< 0.002	18
TAT	0.85	< 0.002	18
PAI-1 antigen	0.60	< 0.007	18
PLT	-0.49	< 0.04	18
Protein C activity	-0.39	< 0.11	18
PT ratio	-0.37	< 0.16	18
D-Dimer	0.36	< 0.14	18
FDP	0.36	< 0.14	18
Protein S antigen	-0.34	< 0.17	18
Protein C antigen	-0.33	< 0.18	18
Plasminogen	-0.31	< 0.22	18
PIC	0.30	< 0.23	18
Fibrinogen	-0.10	< 0.70	18
AT-III	0.035	< 0.90	13
PAI-1 activity	-0.014	< 0.98	13

AT-III, antithrombin-III; DIC, disseminated intravascular coagulation; FDP, fibrin and fibrinogen degradation products; PIC, α_2 plasmin inhibitor–plasmin complex; PLT, platelet count; PT, prothrombin time; TAT, thrombin–antithrombin complex.

Relationships between hypercoagulable state and sepsis or septic MODS have been investigated in recent years [7–13]. The hypercoagulable state, shown by increased levels of PAI-1 [7,8,10,13], TAT [7–9], and prothrombin fragment 1 + 2 [11], and by decreased levels of AT-III [7,9,11,12], factor VII [7,11], and protein C [12], were reported in these studies to be closely related to septic MODS. As mentioned in the Introduction, however, metabolic factors including glucose and fat that are considered to influence those parameters related with coagulopathy are not taken into consideration in those investigations. In our study, performed with strict blood glucose control by AP, the MOF score (mMOF score) was positively correlated with the DIC score, TAT, and tPA–PAI-1 complex, and was negatively correlated with PLT (Tables 7 and 8; Fig. 2). The tPA–PAI-1 complex, which is reported to positively correlate with tPA [42–45], is considered to be a parameter of hypercoagulability and decreased fibrinolysis, and to be closely related with thrombotic diseases [42,43]. The tPA–PAI-1 complex was in fact also positively related with TAT (Table 10) in this study, which is the parameter of hypercoagulability. On the contrary, there were no significant correlations between the MOF score (mMOF score) and parameters related with fibrinolysis (α_2 plasmin inhibitor–plasmin complex, fibrin and fibrinogen degradation products, D-dimer). Judging from the aforementioned results in the present study, hypercoagulability and decreased fibrinolysis, indicated by the increase of

the tPA–PAI-1 complex and TAT, were considered to be closely related with MODS in acutely ill septic patients. The tPA–PAI-1 complex, which is not used for calculating the MOF score and the DIC score, also seemed to be a useful and sensitive marker of MODS.

Moreover, a hypercoagulable state indicated by the elevated tPA–PAI-1 level may be one of the risk factors and predictive markers of MODS. This follows from studies reporting that the hypercoagulable state preceded MODS, in which significant changes of the parameters related with hypercoagulability were found at the onset of sepsis [7]. We also found that changes of the tPA–PAI-1 complex preceded those of organ dysfunctions in some cases (data not shown). These findings suggest that the hypercoagulable state disturbs microcirculation and leads to MODS [8,10].

There were close correlations between MOF score (mMOF score) and TAT and tPA–PAI-1 complex, but no significant correlations between MOF score (mMOF score) and PAI-1, AT-III, and protein C in our study. The reasons for this are not clear, but may be related to the conditions in which our investigation was performed under strict blood glucose control by means of AP, related to the limited number of the patients in our study, or related to the origin of the parameters. PAI-1 is synthesized not only by the endothelium, but also by the liver, vascular smooth muscle cells, and platelets [46]. AT-III is synthesized by the liver and endothelium, and protein C by the liver. On the contrary, the tPA–PAI-1 complex is considered to be synthesized mainly by the activated endothelium, because the tPA–PAI-1 complex is the indicator of tPA, as already mentioned, and tPA is synthesized by the endothelium activated with thrombin, cytokines (eg tumor necrosis factor, interleukin-2), endotoxin, endothelin, catecholamine, histamine, and activated protein C [17,47,48]. A positive correlation between MOF score (mMOF score) and tPA–PAI-1 complex therefore suggests not only a close relationship between organ dysfunction and hypercoagulability, but also an intimate relationship between organ dysfunction and endothelial cell activation.

Endothelial cell injury was closely related with MODS and coagulopathy characterized by hypercoagulability with decreased fibrinolysis, judging from the results that TM was closely correlated with MOF score, DIC score, tPA–PAI-1 complex, TAT, and PLT (Table 9; Figs 3 and 4). These results are consistent with the other reports that endothelial cell activation or injury, which are caused by endotoxin, cytokines, complement, and neutrophils [14–17], causes a hypercoagulable state or DIC, which leads to MODS [14–16]. TM is usually considered to be one of the markers of endothelial cell injury. However, TM also seemed to be a marker of endothelial cell activation in septic patients, because there was positive correlation

between TM and tPA–PAI-1 complex (Table 9), which was considered to be one of the parameters of endothelial cell activation as mentioned earlier.

Conclusion

We investigated acutely ill septic patients with glucose intolerance in which BG was strictly controlled and the glucose tolerance was measured by the glucose clamp method by means of AP, and obtained the following conclusions. The GT did not significantly relate with blood stress related hormone levels, coagulopathy and MODS under strict blood glucose control. Coagulopathy characterized by hypercoagulability with decreased fibrinolysis was closely related with MODS and endothelial cell injury. Among the parameters related with coagulation and fibrinolysis, the tPA–PAI-1 complex, considered to originate from activated endothelium, seemed to be a sensitive parameter of MODS and endothelial cell injury, and might be one of the predictive and risk factors of MODS. Finally, the treatment for reducing hypercoagulability and endothelial cell activation/endothelial cell injury was thought to be justified as one of the therapies for acutely ill septic patients.

Further investigation will, however, be necessary for clarifying these conclusions because the number of the patients we investigated was limited.

Acknowledgement

Most of this study was presented at the 18th and 19th International Symposia on Intensive Care and Emergency Medicine, Belgium, March 1998 and March 1999, respectively.

References

1. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE: **The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.** *Metabolism* 1993, **42**:945–949.
2. Vague IJ, Alessi MC, Vague P: **Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis.** *Diabetologia* 1991, **34**:457–462.
3. Landin K, Tengborn L, Smith U: **Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular diseases.** *J Int Med* 1990, **227**:273–278.
4. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U: **Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.** *Metabolism* 1990, **39**:1044–1048.
5. Juhan-Vague I, Alessi MC, Vague P: **Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus.** *Ann Med* 1996, **28**:371–380.
6. Schneider DJ, Absher PM, Neimane D, Russell JC, Sobel BE: **Fibrinolysis and atherogenesis in the JCR: LA-cp rat in relation to insulin and triglyceride concentrations in blood.** *Diabetologia* 1998, **41**:141–147.
7. Leithauser B, Matthias FR, Nicolai U, Voss R: **Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation?** *Intensive Care Med* 1996, **22**: 631–636.
8. Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Matsuda T: **Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers.** *Blood Coag Fibrinol* 1994, **5**:829–832.

9. Inthorn D, Hoffmann JN, Hartl WH, Muhlhaber D, Jochum M: **Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction.** *Shock* 1997, **8**:328–334.
10. Kidokoro A, Iba T, Fukunaga M, Yagi Y: **Alterations in coagulation and fibrinolysis during sepsis.** *Shock* 1996, **5**:223–228.
11. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J: **Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.** *Blood* 1996, **88**:881–886.
12. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P: **Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.** *Chest* 1992, **101**:816–823.
13. Gando S, Kameue T, Nanzaki S, Nakanishi Y: **Disseminated intravascular coagulation in a frequent complication of systemic inflammatory response syndrome.** *Thromb Haemost* 1996, **75**:224–228.
14. Gando S, Nakanishi Y, Kameue T, Nanzaki S: **Soluble thrombomodulin increases in patients with disseminated intravascular coagulation and in those with multiple organ dysfunction syndrome after trauma: role of neutrophil elastase.** *J Trauma* 1995, **39**:660–664.
15. Nachman RL, Silverstein R: **Hypercoagulable states.** *Ann Intern Med* 1993, **119**:819–827.
16. Endo S, Inada K, Nakae H, Takakuwa T, Kasai T, Yamada Y, Suzuki T, Taniguchi S, Yoshida M: **Blood levels of endothelin-1 and thrombomodulin in patients with disseminated intravascular coagulation and sepsis.** *Res Commun Mol Pathol Pharmacol* 1995, **90**:277–288.
17. Pearson JD: **The control of production and release of haemostatic factors in the endothelial cell.** *Baillieres Clin Haematol* 1993, **6**:629–651.
18. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S: **Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity.** *Arterioscler Thromb* 1991, **11**:183–190.
19. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE: **Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.** *Arterioscler Thromb* 1993, **13**:1822–1828.
20. Maiello M, Boeri D, Podesta F, Cagliero E, Vichi M, Odetti P, Adezati L, Lorenzi M: **Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose.** *Diabetes* 1992, **41**:1009–1015.
21. Pandolfi A, Iacoviello L, Capani F, Vitacolonna E, Donati MB, Consoli A: **Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture.** *Diabetologia* 1996, **39**:1425–1431.
22. Schneider DJ, Sobel BE: **Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids.** *Coronary Artery Dis* 1996, **7**:813–817.
23. Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE: **Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells.** *J Biol Chem* 1998, **273**:8225–8231.
24. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. *Chest* 1992, **101**:1644–1655.
25. Haraguchi Y. **General discussion. Multiple organ failure IV: DIC bleeding from digestive tract.** *J Jpn Assoc Crit Care Med* 1990; **4**:103–144
26. DeFronzo RA, Tobin JD, Andres AR: **Glucose clamp technique: a method for quantifying insulin secretion and resistance.** *Am J Physiol* 1979, **237**:E214–E223
27. Shmueli E, Walker M, Alberti G: **Normal splanchnic but impaired peripheral insulin-stimulated glucose uptake in cirrhosis.** *Hepatology* 1993, **18**:86–95.
28. Aoki N, Hasegawa H. **On the revised form of the confirmatory tests in diagnostic criteria for DIC.** *Annual Report of the Research Committee on Coagulation disorders.* Edited by Aoki N. Tokyo: Ministry of Health and Welfare of Japan, 1988:37–41.
29. Haffner SM: **Cardiovascular risk factors and the prediabetic syndrome.** *Ann Med* 1996, **28**:363–370.
30. Lormeau B, Aourousseau MH, Valensi P, Paries J, Attali JR: **Hyperinsulinemia and hypofibrinolysis: effects of short term optimized glycemic control with continuous insulin infusion in type II diabetic patients.** *Metabolism* 1997, **46**:1074–1079.
31. Lemne C, De Faire U: **Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances.** *Eur J Clin Invest* 1996, **26**:692–697.
32. Jeng JR, Sheu WH, Jeng CY, Huang SH, Shieh SM: **Impaired fibrinolysis and insulin resistance in patients with hypertension.** *Am J Hypertens* 1996, **9**:484–490.
33. Cigolini M, Targher G, Seidell JC, Tonoli M, Schiavon R, Agostino G, De Sandre G: **Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioural variables.** *J Hypertens* 1995, **13**:659–666.
34. Tomiyama H, Kimura Y, Mitsushashi H, Kinouchi T, Yoshida H, Kushiro T, Doba N: **Relationship between endothelial function and fibrinolysis in early hypertension.** *Hypertension* 1998, **31**:321–327.
35. Bavenholm P, Proudler A, Silveira A, Crook D, Blomback M, de Faire U, Hamsten A: **Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease.** *Thromb Haemost* 1995, **73**:568–575.
36. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ: **Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects.** *Diabetes* 1998, **47**:290–293.
37. Lindahl B, Asplund K, Eliasson M, Evrin P-E: **Insulin resistance syndrome and fibrinolytic activity: the northern Sweden MONICA study.** *Int J Epidemiol* 1996, **25**:291–299.
38. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H: **Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.** *Circulation* 1998, **97**:2213–2221.
39. Avellone G, Di Garbo V, Cordova R, Rotolo G, Abruzzese G, Raneli G, De Simone R, Bompiani GD: **Blood coagulation and fibrinolysis in obese NIDDM patients.** *Diabetes Res* 1994, **25**:85–92.
40. Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, Mariani G: **Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.** *Thromb Res* 1992, **67**:643–654.
41. Bavenholm P, de Faire U, Landou C, Efendic S, Nilsson J, Wiman B, Hamsten A: **Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and impaired fibrinolytic function.** *Eur Heart J* 1998, **19**:402–410.
42. Nordenhem A, Wiman B: **Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes.** *Scand J Clin Lab Invest* 1998, **58**:475–784.
43. Yamauchi K, Suzuki T, Furumichi T, Saito H: **Plasma tPA/PAI-1 complex and blood coagulability in patients with coronary artery disease.** *Jpn Heart J* 1992, **33**:351–358.
44. Niwano H, Takahashi H, Tatewaki W, Wada K, Seki Y, Shibata A: **Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.** *Blood Coag Fibrinol* 1992, **3**:389–393.
45. Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T: **Change in plasma levels of tissue plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation.** *Am J Hematol* 1991, **36**:176–183.
46. Sprengers ED, Kluff C: **Plasminogen activator inhibitors.** *Blood* 1987, **2**:381–387.
47. Lijnen HR, Collen D: **Mechanisms of physiological fibrinolysis.** *Baillieres Clin Haematol* 1995, **8**:277–290.
48. Baars JW, de Boer JP, Wagstaff J, Roem D, Eerenberg-Belmer AJ, Nauta J, Pinedo HM, Hack CE: **Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxemia.** *Br J Haematol* 1992, **82**:295–301.